Navigation Links
Cequent Names F. Stephen Laroux, Ph.D., Director, Immunology and Inflammatory Diseases
Date:6/2/2009

CAMBRIDGE, Mass., June 2 /PRNewswire/ -- Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, announced that it has promoted F. Stephen Laroux, Ph.D., to the new position of director, immunology and inflammatory diseases, effective immediately. Dr. Laroux joined the company as a scientist in 2007. Today, he leads the team of Cequent researchers developing drug candidates using Cequent's proprietary tkRNAi delivery platform against a series of targets thought to be important in gastro-intestinal diseases, such as inflammatory bowel disease (IBD). Dr. Laroux's current study portfolio includes the target associated with Cequent's partnership with Novartis, as well as Cequent's in-house IBD program.

"While we are furthest along with our drug candidate CEQ508, an orally administered tkRNAi therapeutic targeting the primary oncogene (beta-catenin, CTNNB1) in FAP (familial adenomatous polyposis) -- our IBD program is actually the company's largest, and Stephen has been critical to our rapid progress over the past 18 months," said Cequent President and CEO, Peter Parker. "We started with fourteen potential therapeutic targets for IBD, including several in our partnership with Novartis. We have finished in vivo testing on candidate treatments against our first four targets, and all have exhibited significant efficacy. This is a testament to the promise of our tkRNAi technology -- but also to Stephen's skills and tenacity in both study design and execution. Thanks to his leadership and hard work we are now positioned to file two IND (investigational new drug) applications with the FDA for IBD therapeutics next year."

Dr. Laroux completed a post-doctoral fellowship at Beth Israel Deaconess Medical Center (BIDMC), Harvard Medical School where he conducted research focused on innate immune responses to bacteria as well as the role of the immune system in chronic disease. Prior to his tenure at BIDMC, Dr. Laroux conducted research into the immunology of diseases such as IBD, rheumatoid arthritis, ischemia-reperfusion, and myocardial infarction, co-authoring more than 40 publications in peer-reviewed journals. Dr. Laroux received a Ph.D. in molecular and cellular physiology (Chancellor's Award) and a master's degree in human physiology, both from Louisiana State University.

About Cequent Pharmaceuticals, Inc. (www.cequentpharma.com)

An early-stage biopharmaceutical company, Cequent is pioneering the development of novel therapeutics to prevent and treat a wide range of human disorders -- from inflammatory disease to cancer -- based on the company's proprietary technology, TransKingdom RNA interference (tkRNAi). Cequent's first products, now in pre-clinical development, are drug candidates targeting colon-cancer prevention and inflammatory bowel disease. The company designed its powerful tkRNAi technology to deactivate specific disease-causing genes safely and effectively, using non-pathogenic bacteria as an engine to produce and deliver RNAi directly into cells. It is based on ground-breaking scientific research originating at the Institut Pasteur (Paris, France) and at the Beth Israel Deaconess Medical Center/Harvard Medical School. A privately held company based in Cambridge, Massachusetts, Cequent was established in 2006.


'/>"/>
SOURCE Cequent Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cequent Names Ted Hibben Chief Business Officer
2. Two Luminaries Join Cequent Scientific Advisory Board: Judy Lieberman, M.D. Ph.D., and Patrice Courvalin, M.D.
3. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
4. Michael D. Taylor, Ph.D., Joins Cequent Pharmaceuticals Board of Directors
5. Lexicon Names Ajay Bansal Executive Vice President and Chief Financial Officer
6. AIAA names top ten emerging aerospace technologies of 2009
7. Microbia, Inc. Names Alex Chu as Vice President of Process Development
8. Premier Research Names Hal Ward, R.Ph., PharmD as Executive Director, Global Pharmacovigilance
9. Pulmonary Hypertension Association Names Dr. Nicholas Hill Recipient of 2009 Award of Excellence in Pulmonary Arterial Hypertension (PAH) Care
10. Orexigen(R) Therapeutics Names Michael Scaife Senior Vice President of Regulatory Affairs and Product Development, Contrave(R) Program
11. Hospira Names Brian Meadows Supply Chain Chief
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... ... April 20, 2017 , ... USDM Life Sciences ... life sciences and healthcare industries, is pleased to announce Holger Braemer as ... subsidiary “USDM Europe GmbH” based in Germany. , Braemer is an integral part ...
(Date:4/20/2017)... , ... April 20, 2017 , ... NetDimensions appoints Bill ... , With over 20 years of experience in the learning technologies industry, Mastin joins ... company within Learning Technologies Group plc (LTG). At LEO, Mastin served as SVP of ...
(Date:4/20/2017)... ... 2017 , ... Energetiq Technology , a world leader ... Executive Officer (CEO) Debbie Gustafson has been appointed to the SEMI North America ... the electronics manufacturing supply chain. The mission of the SEMI NAAB is to ...
(Date:4/20/2017)... ... April 20, 2017 , ... ... a unique intellectual property (IP) sharing and commercialization model. , The Center for ... A main component of this effort is bringing the IP to the attention ...
Breaking Biology Technology:
(Date:3/22/2017)... , March 21, 2017 Vigilant Solutions ... serving law enforcement agencies, announced today the appointment of ... director of public safety business development. Mr. ... enforcement experience, including a focus on the aviation transportation ... most recent position, Mr. Sheridan served as the Aviation ...
(Date:3/13/2017)... 13, 2017 Future of security: Biometric Face Matching software  ... ... DERMALOGs Face Matching enables to match face pictures against each other ... identify individuals. (PRNewsFoto/Dermalog Identification Systems) ... DERMALOG,s "Face Matching" is the fastest software for biometric Face Matching on the ...
(Date:3/7/2017)... 2017   HireVue , the leading provider of ... the best talent, faster, today announced the additions of ... and Diana Kucer as Chief Marketing Officer ... team poised to drive continued growth in the company,s ... of record bookings in 2017. "Companies worldwide ...
Breaking Biology News(10 mins):